Corporate Governance

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination committee

The 2026 Annual General Meeting (AGM) will be held on May 6, 2026 in Stockholm.

The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on May 6, 2025, comprises the following members:

James Brush, appointed by Frazier Life Sciences

Peter Lindell, appointed by Cidro Förvaltning AB

Peder Walberg, appointed by Cetoros AB

Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.

The Committee’s assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2026.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email to [email protected] (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 16, 2026.

The Instructions to the Nomination Committee, which were adopted by the AGM on May 6, 2025, can be found under Item 13 in the Notice of the AGM 2025.

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]